Aurobindo Pharma Limited is set to expand its presence in the antiretroviral (ARV) segment and improve access to AIDS treatments post tentative approval from the US Food and Drug Administration (FDA) for the first generic dispersible tablet formulation of a fixed dose combination of abacavir, lamivudine and dolutegravir.
Aurobindo’s Pediatric AIDS Combo Generic Approved; Eugia Restructuring Back On Cards
6-7 Biosimilars In Regulated Markets By 2028
A US FDA tentative approval for Aurobindo’s dolutegravir combination generic for children should increase access under the PEPFAR program and aid sales. On a Q1 earnings call, renewed efforts to restructure Eugia, biosimilar launch plans and fallouts of oral drug shortages and damage to Pfizer’s US injectables warehouse were discussed
